University of Pittsburgh researchers have engineered a next-generation soluble CD4-D1 domain with enhanced stability and extended in vivo half-life, designed to serve as a potent HIV entry inhibitor. This novel CD4-D1 variant exhibits broad HIV neutralization and avoids the immunosuppressive effects associated with traditional soluble CD4 (sCD4) treatments. This innovation could significantly advance HIV prevention strategies by providing a long-acting, highly stable, and effective HIV entry inhibitor.